血浆总tau多基因风险评分与阿尔茨海默病及轻度认知障碍的纵向关联
该纵向队列研究基于HELIAD队列618名基线认知正常老年人(平均73.37岁,随访2.92±0.80年),发现血浆t-tau多基因风险评分(PRStau)每增加1个标准差,AD/aMCI风险增加29%(HR 1.290,95%CI 1.006-1.654);在英国生物银行142,637名参与者中验证了类似关联(HR 1.046,95%CI 1.007-1.086)。
要点
- PRStau每升高1个SD与AD/aMCI风险增加29%相关(HELIAD队列)。
- 女性(HR 1.451)和较年轻参与者(HR 1.866)中关联更强,男性和高龄者未达统计学显著。
- UK Biobank大样本验证PRStau与AD风险轻度升高相关(HR 1.046)。
核心结论
- 血浆t-tau多基因风险评分与AD/aMCI发病风险呈正相关,可能作为tau病理遗传倾向的早期指标。
- 遗传易感性与AD病理的关联可能受性别和年龄影响,风险建模时应考虑这些因素。
研究设计与样本
- 纵向队列研究,使用HELIAD研究数据,纳入618名65岁及以上、基线无AD或遗忘型轻度认知障碍(aMCI)的认知健康参与者。
- 在英国生物银行(UKB)60岁及以上无痴呆参与者(n=142,637)中进行重复验证。
- 主要暴露为基于与血浆tau水平相关的常见遗传变异构建的PRStau,主要结局为aMCI或AD发病。
主要发现
- HELIAD队列平均随访2.92±0.80年,73人发展为AD/aMCI;PRStau每增加1个SD,AD/aMCI风险增加29%(HR 1.290,95%CI 1.006-1.654)。
- 分层分析显示女性HR 1.451(95%CI 1.023-2.058),较年轻参与者HR 1.866(95%CI 1.175-2.962),男性和高龄参与者结果未达统计学显著。
- UKB样本平均随访12.9±2.4年,2,737人发展为AD;PRStau升高与AD风险增加相关(HR 1.046,95%CI 1.007-1.086)。
关键数值与推荐
- HELIAD队列中PRStau每升高1个SD对应AD/aMCI风险HR 1.290(95%CI 1.006-1.654)。
- 女性亚组HR 1.451(95%CI 1.023-2.058),较年轻亚组HR 1.866(95%CI 1.175-2.962)。
- UKB队列中PRStau每升高1个SD对应AD风险HR 1.046(95%CI 1.007-1.086)。
临床怎么用
- PRStau可能作为AD/aMCI遗传风险的早期筛查指标,辅助现有诊断和风险分层算法。
- 在AD遗传风险建模中应考虑性别和年龄的效应修饰作用。
局限性
- HELIAD队列随访时间较短(2.92±0.80年),事件数较少(73例)。
- 男性和高龄参与者中关联未达统计学显著,需更大样本验证。
- 研究未报告PRStau的具体构建细节及临床效用评估。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Elevated levels of total tau (t-tau) are a key biomarker of neurodegeneration, often seen in Alzheimer disease (AD). Identifying individuals at increased risk of AD using minimally invasive biomarkers can enable early intervention. We developed a polygenic risk score (PRS) for plasma t-tau and examined its association with the risk for developing clinical endophenotypes of AD pathology. METHODS: This longitudinal cohort study used data from the Hellenic Longitudinal Investigation of Aging and Diet (HELIAD) study, involving individuals aged 65 years or older, free of AD, or amnestic mild cognitive impairment (aMCI-an AD prodrome) at baseline. Our primary exposure was PRStau, a PRS based on common genetic variants linked to plasma tau levels. The primary outcome was aMCI or AD incidence. We assessed the association between PRStau levels and aMCI/AD risk using Cox regression models adjusted for age, sex, education, APOE ε4 allele carriership, and population structure. We sought replication in a sample of UK Biobank (UKB) participants aged 60 years or older without prevalent dementia. RESULTS: In the HELIAD sample, among 618 cognitively healthy participants (mean age 73.37 years, 58.4% female), followed for 2.92 ± 0.80 years, 73 developed AD/aMCI. A 1 SD increase in PRStau was linked to a 29% higher AD/aMCI risk (hazard ratio [HR] 1.290, 95% CI 1.006-1.654). Stratified analyses revealed greater effect estimates in women (HR 1.451, 95% CI 1.023-2.058) and younger participants (HR 1.866, 95% CI 1.175-2.962), whereas results in men and older participants did not reach statistical significance. In the UKB sample (n = 142,637, mean age 64.2 years, 52% female), 2,737 participants developed AD over 12.9 ± 2.4 years of follow-up. Higher PRStau was also linked to increased AD risk (HR 1.046, 95% CI 1.007-1.086). DISCUSSION: These results support the potential utility of PRS for plasma t-tau in predicting AD/aMCI incidence. The relationship between genetic predisposition for elevated plasma t-tau levels and AD pathology might be influenced by sex and age, suggesting that these factors should be considered in AD genetic risk modeling. PRS could serve as an early indicator of genetic propensity for tau pathology, enhancing existing AD diagnostic and risk stratification algorithms.
引用
- Mourtzi N, Charisis S, Ntanasi E, et al. Longitudinal Association of a Polygenic Risk Score for Plasma T-Tau With Incident Alzheimer Dementia and Mild Cognitive Impairment. Neurology. 2025. PMID: 41043097. doi:10.1212/WNL.0000000000213904
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。